Faced with harsh criticism for approving a controversial drug for all Alzheimer’s patients, the Food and Drug Administration has largely narrowed his recommendationsuggests that only those with mild memory or thinking problems should take it. The FDA’s turn, quite unusual for a drug that has only been on the market for a few weeks, could […]